HomeCompareOPHLY vs MRK

OPHLY vs MRK: Dividend Comparison 2026

OPHLY yields 3.41% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OPHLY wins by $782.52M in total portfolio value
10 years
OPHLY
OPHLY
● Live price
3.41%
Share price
$5.29
Annual div
$0.18
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$782.58M
Annual income
$740,792,960.47
Full OPHLY calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — OPHLY vs MRK

📍 OPHLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOPHLYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OPHLY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OPHLY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OPHLY
Annual income on $10K today (after 15% tax)
$289.50/yr
After 10yr DRIP, annual income (after tax)
$629,674,016.40/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, OPHLY beats the other by $629,665,687.99/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OPHLY + MRK for your $10,000?

OPHLY: 50%MRK: 50%
100% MRK50/50100% OPHLY
Portfolio after 10yr
$391.32M
Annual income
$370,401,379.31/yr
Blended yield
94.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

OPHLY
Analyst Ratings
2
Sell
Consensus: Sell
Altman Z
5.0
Piotroski
8/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OPHLY buys
0
MRK buys
0
PoliticianChamberTickerTypeAmountDate
Daniel Goldman🏢 House$OPHLY▼ Sell$15,001 - $50,0002023-07-10
Daniel Goldman🏢 House$OPHLY▼ Sell$1,001 - $15,0002023-07-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOPHLYMRK
Forward yield3.41%2.76%
Annual dividend / share$0.18$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$782.58M$56.8K
Annual income after 10y$740,792,960.47$9,798.13
Total dividends collected$779.53M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusSellBuy

Year-by-year: OPHLY vs MRK ($10,000, DRIP)

YearOPHLY PortfolioOPHLY Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,381$681.17$11,206$366.19+$175.00OPHLY
2$13,627$1,449.07$12,650$502.35+$977.00OPHLY
3$17,824$3,243.01$14,407$694.19+$3.4KOPHLY
4$27,000$7,928.61$16,585$967.82+$10.4KOPHLY
5$51,340$22,449.56$19,342$1,363.89+$32.0KOPHLY
6$134,722$79,788.74$22,913$1,947.19+$111.8KOPHLY
7$535,510$391,357.72$27,662$2,823.89+$507.8KOPHLY
8$3,480,692$2,907,695.93$34,159$4,173.35+$3.45MOPHLY
9$39,050,210$35,325,869.63$43,337$6,308.80+$39.01MOPHLY
10$782,576,685$740,792,960.47$56,776$9,798.13+$782.52MOPHLY

OPHLY vs MRK: Complete Analysis 2026

OPHLYStock

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.

Full OPHLY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this OPHLY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OPHLY vs SCHDOPHLY vs JEPIOPHLY vs OOPHLY vs KOOPHLY vs MAINOPHLY vs JNJOPHLY vs ABBVOPHLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.